This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Fallini B, Brunetti L, Sportoletti P, Martelli M. NPM1-mutated acute myeloid leukemia: From bench to bedside. Blood. 2020; 136: 1707–1721.FalliniBBrunettiLSportolettiPMartelliMNPM1-mutated acute myeloid leukemia: From bench to bedside20201361707172110.1182/blood.201900422632609823Search in Google Scholar
Metzeler K, Herold T, Rothenberg-Turley M, Amler S, Sauerland M, Gorlich D, Schneider S, Konstandin N, Dufour A, Braundl K, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016; 128: 686–698.MetzelerKHeroldTRothenberg-TurleyMAmlerSSauerlandMGorlichDSchneiderSKonstandinNDufourABraundlKSpectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia201612868669810.1182/blood-2016-01-69387927288520Search in Google Scholar
Hassan N, Said F, Shafik R, Abdellateif M. Dysregulation of CCAAT/enhancer binding protein-alpha (CEBPA) expression in the bone marrow of acute myeloid leukemia patients. Egypt J Med. Hum Genet. 2021; 22.HassanNSaidFShafikRAbdellateifMDysregulation of CCAAT/enhancer binding protein-alpha (CEBPA) expression in the bone marrow of acute myeloid leukemia patients20212210.1186/s43042-021-00154-zSearch in Google Scholar
Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M, Neubauer A, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99: 4326–4335.ThiedeCSteudelCMohrBSchaichMSchakelUPlatzbeckerUWermkeMBornhauserMRitterMNeubauerAAnalysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis2002994326433510.1182/blood.V99.12.4326Search in Google Scholar
Gilliland G, Griffin J. The role of FLT3 in hematopoiesis and leukemia. Blood. 2002;100: 1532–1542.GillilandGGriffinJThe role of FLT3 in hematopoiesis and leukemia20021001532154210.1182/blood-2002-02-049212176867Search in Google Scholar
Papaemmanuil E, Grstung M, Bullinger L, Gaidzik V, Paschka P, Roberts N, Potter N, Heuser M, Thol F, Bolli N, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374: 2209–2221.PapaemmanuilEGrstungMBullingerLGaidzikVPaschkaPRobertsNPotterNHeuserMTholFBolliNGenomic classification and prognosis in acute myeloid leukemia20163742209222110.1056/NEJMoa1516192497999527276561Search in Google Scholar
Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum F, Buchner T, Dombret H, Ebert B, Fenaux P, Larson R, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129: 424–447.DöhnerHEsteyEGrimwadeDAmadoriSAppelbaumFBuchnerTDombretHEbertBFenauxPLarsonRDiagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel201712942444710.1182/blood-2016-08-733196529196527895058Search in Google Scholar
The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368: 2059–2074.The Cancer Genome Atlas Research NetworkGenomic and epigenomic landscapes of adult de novo acute myeloid leukemia20133682059207410.1056/NEJMoa1301689376704123634996Search in Google Scholar
Herold T, Rothenberg-Thurley M, Grunwald V, Janke H, Goerlich D, Sauerland M, Konstandin N, Dufour A, Schneider S, Neusser M, et al. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2020; 34: 3161–3172.HeroldTRothenberg-ThurleyMGrunwaldVJankeHGoerlichDSauerlandMKonstandinNDufourASchneiderSNeusserMValidation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia2020343161317210.1038/s41375-020-0806-0768597532231256Search in Google Scholar
Dalenc F, Drouet J, Ader I, Delmas C, Rochaix P, Favre G, Cohen-Jonathen E, Toulas C. Increased expression of a COOH-truncated nucleophosmin resulting from alternative splicing is associated with cellular resistance to ionizing radiation in HeLa cells. Int J Cancer. 2002; 100: 662–668.DalencFDrouetJAderIDelmasCRochaixPFavreGCohen-JonathenEToulasCIncreased expression of a COOH-truncated nucleophosmin resulting from alternative splicing is associated with cellular resistance to ionizing radiation in HeLa cells200210066266810.1002/ijc.1055812209603Search in Google Scholar
Ahn J, Liu X, Cheng D, Peng J, Chan P, Wade P, Ye K. Nucleophosmin/B23, a nuclear PI(3,4,5)P(3) receptor, mediates the antiapoptotic actions of NGF by inhibiting CAD. Mol Cell. 2005; 18: 435–445.AhnJLiuXChengDPengJChanPWadePYeKNucleophosmin/B23, a nuclear PI(3,4,5)P(3) receptor, mediates the antiapoptotic actions of NGF by inhibiting CAD20051843544510.1016/j.molcel.2005.04.01015893727Search in Google Scholar
Eirin-Lopez JM, Frehlick L, Ausio J. Long-term evolution and functional diversification in the members of the nucleophosmin/nucleoplasmin family of nuclear chaperones. Genetics. 2006; 173: 1835–1850.Eirin-LopezJMFrehlickLAusioJLong-term evolution and functional diversification in the members of the nucleophosmin/nucleoplasmin family of nuclear chaperones20061731835185010.1534/genetics.106.058990156971216751661Search in Google Scholar
Lee S, Park J, Kim S, Park E, Yun Y, Kwon J. A proteomics approach for the identification of nucleophosmin and heterogenous nuclear ribonucleoprotein C1/C2 as chromatin-biding proteins in response to DNA double-strand breaks. Biochem J. 2005; 388: 7–15.LeeSParkJKimSParkEYunYKwonJA proteomics approach for the identification of nucleophosmin and heterogenous nuclear ribonucleoprotein C1/C2 as chromatin-biding proteins in response to DNA double-strand breaks200538871510.1042/BJ20042033118668815737070Search in Google Scholar
Zatsepina O, Rousselet A, Chan P, Olson M, Jordan E, Bornens M. The nucleolar phosphoprotein B23 redistributes in part to the spindle poles during mitosis. J Cell Sci. 1999; 112: 455–466.ZatsepinaORousseletAChanPOlsonMJordanEBornensMThe nucleolar phosphoprotein B23 redistributes in part to the spindle poles during mitosis199911245546610.1242/jcs.112.4.4559914158Search in Google Scholar
Fallini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A, Bigerna B, Pasqualucci L, Mannucci R, Rosati R, et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood. 2006, 107, 4514–4523.FalliniBBolliNShanJMartelliMPLisoAPucciariniABigernaBPasqualucciLMannucciRRosatiRBoth carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML20061074514452310.1182/blood-2005-11-474516455950Search in Google Scholar
Fallini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with normal karyotype. N Engl J Med. 2005; 352: 254–266.FalliniBMecucciCTiacciEAlcalayMRosatiRPasqualucciLLa StarzaRDiverioDColomboESantucciACytoplasmic nucleophosmin in acute myelogenous leukemia with normal karyotype200535225426610.1056/NEJMoa04197415659725Search in Google Scholar
Rau R, Rodriguez B, Luo M, Jeong M, Rosen A, Rogers J, Campbell C, Daigle S, Deng L, Song Y, et al. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood. 2016; 128: 971–981.RauRRodriguezBLuoMJeongMRosenARogersJCampbellCDaigleSDengLSongYDOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia201612897198110.1182/blood-2015-11-684225499085627335278Search in Google Scholar
Cocciardi S, Dolnik A, Kapp-Schwoerer S, Rucker F, Lux S, Blatte T, Skambraks S, Kronke J, Heidel F, Schnoder T, et al. Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nat Commun. 2019: 10:2031.CocciardiSDolnikAKapp-SchwoererSRuckerFLuxSBlatteTSkambraksSKronkeJHeidelFSchnoderTClonal evolution patterns in acute myeloid leukemia with NPM1 mutation201910203110.1038/s41467-019-09745-2649771231048683Search in Google Scholar
Lagunas-Rangel F, Chavez-Valencia V, Gomez-Guijosa M, Cortes-Penagos C. Acute myeloid leukemia - genetic alterations and their clinical prognosis. IJHOSCR. 2017; 4: 328–339.Lagunas-RangelFChavez-ValenciaVGomez-GuijosaMCortes-PenagosCAcute myeloid leukemia - genetic alterations and their clinical prognosis20174328339Search in Google Scholar
Gorello P, Cazzaniga G, Alberti F, Dell’Oro M, Gottardi E, Specchia G, Roti G, Rosati R, Martelli M, Diverio D, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia. 2006; 20: 1103–1108.GorelloPCazzanigaGAlbertiFDell’OroMGottardiESpecchiaGRotiGRosatiRMartelliMDiverioDQuantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations2006201103110810.1038/sj.leu.240414916541144Search in Google Scholar
Libura M, Pawełczyk M, Florek I, Matiakowska K, Jaźwiec B, Borg K, Solarska I, Zawada M, Czekalska S, Libura J, et al. CEBPA copy number variations in normal karyotype acute myeloid leukemia: possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis. Blood Cells Mol Dis. 2015; 55: 284–292.LiburaMPawełczykMFlorekIMatiakowskaKJaźwiecBBorgKSolarskaIZawadaMCzekalskaSLiburaJCEBPA copy number variations in normal karyotype acute myeloid leukemia: possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis20155528429210.1016/j.bcmd.2015.07.00226460249Search in Google Scholar
Nakao M, Yokota S, Iwai T, Kaneko H, Kashima K, Sonoda Y, Fujimoto T, Misawa S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996; 10: 1911–1918.NakaoMYokotaSIwaiTKanekoHKashimaKSonodaYFujimotoTMisawaSInternal tandem duplication of the flt3 gene found in acute myeloid leukemia19961019111918Search in Google Scholar
Sallmyr A, Fan J, Datta K, Kim KT, Grosu D, Shapiro P, Small D, Rassool F. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: Implications for poor prognosis in AML. Blood. 2008; 111: 3173–3182.SallmyrAFanJDattaKKimKTGrosuDShapiroPSmallDRassoolFInternal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: Implications for poor prognosis in AML20081113173318210.1182/blood-2007-05-09251018192505Search in Google Scholar
Schnittger S, Bacher U, Haferlach C, Alpermann T, Kern W, Haferlach T. Diversity of the juxtamembrane and TKD1 mutations (exons 13–15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data. Genes Chromosomes Cancer. 2012; 51: 910–924.SchnittgerSBacherUHaferlachCAlpermannTKernWHaferlachTDiversity of the juxtamembrane and TKD1 mutations (exons 13–15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data20125191092410.1002/gcc.2197522674490Search in Google Scholar
Daver N, Venugopal S, Ravandi F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J. 2021; 11: 104.DaverNVenugopalSRavandiFFLT3 mutated acute myeloid leukemia: 2021 treatment algorithm20211110410.1038/s41408-021-00495-3815992434045454Search in Google Scholar
Pabst T, Mueller B, Zhang P, Radomska H, Narravyla S, Schnittger S, Behre G, Hiddemann W, Tenen W. Dominant-negative mutations of CEBPA, encoding CCAAt/enhancer biding protein-α (C/EBPα), in acute myeloid leukemia. Nat Genet. 2001; 27: 263–270.PabstTMuellerBZhangPRadomskaHNarravylaSSchnittgerSBehreGHiddemannWTenenWDominant-negative mutations of CEBPA, encoding CCAAt/enhancer biding protein-α (C/EBPα), in acute myeloid leukemia20012726327010.1038/8582011242107Search in Google Scholar
Su L, Shi YY, Liu ZY, Gao SJ. Acute myeloid leukemia with CEBPA muttions: Current progress and future directions. Front Oncol. 2022; 12: 806137.SuLShiYYLiuZYGaoSJAcute myeloid leukemia with CEBPA muttions: Current progress and future directions20221280613710.3389/fonc.2022.806137884402035178345Search in Google Scholar
Ley T, Ding L, Walter M, McLellan M, Lamprecht T, Larson D, Kandoth C, Payton J, Baty J, Welch J, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363: 2424–2433.LeyTDingLWalterMMcLellanMLamprechtTLarsonDKandothCPaytonJBatyJWelchJDNMT3A mutations in acute myeloid leukemia20103632424243310.1182/blood.V118.21.SCI-31.SCI-31Search in Google Scholar
Godfrey L, Crump N, Thorne R, Lau IJ, Repapi E, Dimou D, Smith A, Harman J, Telenius J, Oudelaar A, et al. DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation. Nat Commun. 2019; 10: 2803.GodfreyLCrumpNThorneRLauIJRepapiEDimouDSmithAHarmanJTeleniusJOudelaarADOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation201910280310.1038/s41467-019-10844-3659495631243293Search in Google Scholar